title: Potentiated antitumor effects of interleukin 12 and interferon alpha against B16F10 melanoma in mice.
abstract: Systemic administration of cytokines has not found broad application in cancer immunotherapy due to its toxicity and lack of effectiveness in a broad spectrum of tumors. Among the most promising cytokines used often in pre-clinical and clinical trials are interferon alpha and interleukin 12. We have shown in our study that combining IL-12 with IFN-alpha in a dose which alone does not show antitumor activity results in potentiated antitumor effects without inducing toxicity.
authors.affiliation: Department of Immunology, Center of Biostructure, Medical University of Warsaw, Poland.
authors.forename: A
authors.initials: A
authors.lastname: Dabrowska
authors.forename: A
authors.initials: A
authors.lastname: Giermasz
authors.forename: J
authors.initials: J
authors.lastname: Gołab
authors.forename: M
authors.initials: M
authors.lastname: Jakóbisiak
mesh_terms: D000276:Adjuvants, Immunologic / Q000627:therapeutic use*; D000818:Animals; D000970:Antineoplastic Agents / Q000627:therapeutic use*; D007167:Immunotherapy / Q000379:methods*; D016898:Interferon-alpha / Q000627:therapeutic use*; D018664:Interleukin-12 / Q000627:therapeutic use*; D008546:Melanoma, Experimental / Q000188:drug therapy*; D051379:Mice; D008810:Mice, Inbred C57BL; D008811:Mice, Inbred DBA; D009368:Neoplasm Transplantation; D013997:Time Factors; D014407:Tumor Cells, Cultured
chemical_list: D000276:Adjuvants, Immunologic; D000970:Antineoplastic Agents; D016898:Interferon-alpha; D018664:Interleukin-12